- AstraZeneca (NASDAQ:AZN) is up 2% premarket on average volume in response to its announcement of positive results from a Phase 3 clinical trial, OLYMPIAD, assessing LYNPARZA (olaparib) compared to standard-of-care chemotherapy for the treatment of patients with HER2-negative, BRCA1- or BRCA2-positive breast cancer.
- Patients receiving LYNPARZA showed a statistically significant improvement in progression-free survival (PFS) compared to chemotherapy (capecitabine, vinorelbine or eribulin).
- EVP, Global Medicines Development and Chief Medical Officer Sean Bohen says, "These results are positive news for patients with BRCA-mutated metastatic breast cancer, a disease with a high unmet need, and are the first positive Phase III data for a PARP inhibitor beyond ovarian cancer. This is highly encouraging for the development of our broad portfolio which aims to treat multiple cancers by targeting DNA damage response pathways."
- The results will be submitted for presentation at an upcoming medical meeting. Regulatory applications are being prepared.
-
LYNPARZA is currently approved to treat BRCA-positive ovarian cancer.